Member driven initiatives
Subject/Title: Canada-Israel Cardiovascular Innovation (CICI) Forum Event
First name: Liz
Last name: Thuo
The Organizing Committee of the Canada-Israel Cardiovascular Innovation (CICI) Forum is pleased to announce the results of the 2022 CICI competition. Canadian applications were reviewed by Israeli reviewers, and Israeli applications were reviewed primarily by Canadian reviewers. The top six applicants who have been selected to present at the CICI Forum on May 15, 2022 are:
Company: Biobeat Technologies Ltd. (Israel)
Applicant: Arik Eisenkraft
Innovation: Remote Cardiac Rehabilitation Using an Advanced Noninvasive Wireless Wearable monitoring platform in High-Risk Heart Failure Patients
Company: Coramaze Technologies Ltd. (Israel)
Applicant: Ido Sadan
Innovation: Tripair – Next Generation Percutaneous Treatment for Heart Failure Patients
Company: RBY Medical (Canada)
Applicant: Bradley Strauss
Innovation: Angioplasty Support Sleeve for Peripheral Arterial Interventions
Company: Selfit Therapist Robot (Israel)
Applicant: Shahar Figelman
Innovation: Selfit Therapist Robot
Company: VenoVision (Israel)
Applicant: Jonathan Maron
Innovation: VenoVision Hemodynamic Remote Monitoring Platform
Company: PLAKK Inc. (Canada)
Applicant: Kashif Khan
Innovation: Saving Lives One Scan at a Time: An Artificial Intelligence-Powered Ultrasound Analysis Tool to Characterize and Detect Unstable Plaques
Our Keynote Speaker for the event is Peter J. Fitzgerald, MD, PhD of Stanford University and Triventures (see bio below). Dr. Fitzgerald will present a talk on “Digital Health Innovation: Advice for Early Stage Start-ups”.
CICI Forum Registration
We invite you to attend the CICI Forum that will take place, virtually, on Sunday, May 15, 2022 at 12 pm EDT / 7 Pm IDT to listen to the presentations from our top 6 finalists.
Registration: There is no fee to attend. Visit https://www.cicvinnovation.com/attend to register.
About the CICI: To read more about the CICI, please visit https://www.cicvinnovation.com/.
Keynote Speaker Bio:
Peter Fitzgerald, MD, PhD
Interventional Cardiologist and Professor Emeritus in the Departments of Medicine and Engineering at Stanford
Director of the Center for Cardiovascular Technology at Stanford University Medical School
Director of the Cardiovascular Core Analysis Laboratory (CCAL) at Stanford University Medical School
Co-founder/Managing Partner at Triventures
Dr. Peter Fitzgerald is the Director of the Center for Cardiovascular Technology and Director of the Cardiovascular Core Analysis Laboratory (CCAL) at Stanford University Medical School. He is an Interventional Cardiologist and has a PhD in Engineering. He is Professor in both the Departments of Medicine and Engineering (by courtesy) at Stanford. Presently, Dr. Fitzgerald’s laboratory includes 17 postdoctoral fellows and graduate engineering students focusing on state-of-the-art technologies in Cardiovascular Medicine. He has led or participated in over 175 clinical trials, published over 550 manuscripts/chapters, and lectures worldwide. He has trained over 150 post-docs in Engineering and Medicine in the past decade. In addition, he heads the Stanford/Asia MedTech innovation program.
Dr. Fitzgerald has been principle/founder of twenty-four medical device companies in the San Francisco Bay Area. He has transitioned eighteen of these start-ups to large medical device companies. He serves on several boards of directors, advised dozens of medical device startups as well as multinational healthcare companies in the design and development of new diagnostic and therapeutic devices in the cardiovascular arena. In 2001, Peter was on the founding team of LVP Capital, a venture firm, focused on medical device and biotechnology start-ups in San Francisco. In 2009, he co-founded Triventures, which is an incubator/venture fund for early stage medical technology in Israel.